Abstract
Molecules that inhibit histone deacetylases (HDACs) activity have shown a great promise as anticancer agents since they interfere with cell proliferation and angiogenesis, induce cell differentiation and promote apoptosis. A number of HDACIs (for example: SAHA) have been approved by FDA for the treatment of cancer in different stages of clinical trials. HDAC inhibition proves to be a worthy strategy for cancer therapy. Thus, the distribution and metabolism of HDACIs in vivo are of significant clinical value for diagnosis and assessment of therapeutic efficacy. Molecular imaging is one of the primary tools used to noninvasively evaluate biological processes at the cellular and molecular level in living subjects. Various imaging modalities, including optical bioluminescence/ fluorescence, PET, SPECT, MRI, CT and US are all successfully used to assess the anatomic or functional dissemination of tissues and specific molecular targets, such as imaging molecular interactions, tumor vitality, apoptosis, angiogenesis and response to cancer treatment in the body. The utility of molecular imaging for monitoring HDACIs provides a perfect strategy for deeper understanding about cancer. In this article, the recent progresses of molecular imaging for assessing HDACIs are reviewed. In addition, how imaging can be used, at least experimentally, to assess specific molecular targets is also discussed.
Keywords: Histone deacetylase, Histone deacetylase inhibitors, Cancer therapy, Molecular imaging, PET, Optical imaging, TOMO- GRAPHY, Myeloma, Colon Carcinoma, Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Volume: 12 Issue: 3
Author(s): Huang Jiaguo, Liu Zhiguo and Zeng Wenbin
Affiliation:
Keywords: Histone deacetylase, Histone deacetylase inhibitors, Cancer therapy, Molecular imaging, PET, Optical imaging, TOMO- GRAPHY, Myeloma, Colon Carcinoma, Brain Cancer
Abstract: Molecules that inhibit histone deacetylases (HDACs) activity have shown a great promise as anticancer agents since they interfere with cell proliferation and angiogenesis, induce cell differentiation and promote apoptosis. A number of HDACIs (for example: SAHA) have been approved by FDA for the treatment of cancer in different stages of clinical trials. HDAC inhibition proves to be a worthy strategy for cancer therapy. Thus, the distribution and metabolism of HDACIs in vivo are of significant clinical value for diagnosis and assessment of therapeutic efficacy. Molecular imaging is one of the primary tools used to noninvasively evaluate biological processes at the cellular and molecular level in living subjects. Various imaging modalities, including optical bioluminescence/ fluorescence, PET, SPECT, MRI, CT and US are all successfully used to assess the anatomic or functional dissemination of tissues and specific molecular targets, such as imaging molecular interactions, tumor vitality, apoptosis, angiogenesis and response to cancer treatment in the body. The utility of molecular imaging for monitoring HDACIs provides a perfect strategy for deeper understanding about cancer. In this article, the recent progresses of molecular imaging for assessing HDACIs are reviewed. In addition, how imaging can be used, at least experimentally, to assess specific molecular targets is also discussed.
Export Options
About this article
Cite this article as:
Jiaguo Huang, Zhiguo Liu and Wenbin Zeng, Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228779
DOI https://dx.doi.org/10.2174/187152012800228779 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Designing Novel Molecules for Anti-Cancer Enzyme Modulation: A Mechanistic and Therapeutic Perspective
The deficiencies or hyper functions of enzymes cause a number of diseases. Enzyme inhibition is an important area of pharmaceutical research since studies in this field have already led to the discovery of wide variety of drugs useful in a number of diseases. Specific inhibitors interact with enzymes and block ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy
The thematic issue, "Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy," explores the critical role of heterocyclic compounds in advancing the frontiers of cancer treatment. Heterocycles serve as fundamental building blocks in medicinal chemistry due to their structural diversity and ability to interact with biological targets. This issue aims ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reality Check: Cancer Stem Cell Route to Cancer
Current Biotechnology Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry A Review on the Role of Nanosensors in Detecting Cellular miRNA Expression in Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy
Current Cancer Drug Targets Critical Review of the Simple Theoretical Models in Dynamic Imaging: Up-Slope Method and Graphical Analysis
Current Radiopharmaceuticals Nitric Oxide Synthase (NOS) Inhibitors in Cancer Angiogenesis
Current Enzyme Inhibition Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Using Free and Open-Source Bioconductor Packages to Analyze Array Comparative Genomics Hybridization (aCGH) Data
Current Genomics Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
Current Neuropharmacology Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Immune Checkpoint Inhibitors: Basics and Challenges
Current Medicinal Chemistry Brain Tumor Segmentation Using Deep Belief Networks and Pathological Knowledge
CNS & Neurological Disorders - Drug Targets Automated Brain Tumor Detection using Ideal Shallow Neural Network with Artificial Jellyfish Optimization
Current Medical Imaging Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry Recent Progress in the Application of Exosome Analysis in Ovarian Cancer Management
Current Cancer Drug Targets Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry